Molecular docking based screening of Noggin inhibitors

Area of Science:

• Oncology
• Biochemistry
• Pharmacology

Background:

• Noggin (NOG), a bone morphogenetic protein (BMP) antagonist, promotes breast cancer metastasis to bone.
• This metastasis leads to painful osteolytic lesions, highlighting NOG as a critical therapeutic target.
• Targeting NOG could impede bone metastasis and alleviate patient suffering.

Purpose of the Study:

• To identify novel small molecule inhibitors of Noggin (NOG) for potential therapeutic application in breast cancer bone metastasis.
• To explore the feasibility of targeting NOG through structure-based virtual screening.
• To discover tool compounds for further investigation of BMP pathway functions.

Main Methods:

• Structure-based virtual screening of 8.5 million ligands from the e-molecule database against a novel NOG binding site using the GLIDE algorithm.
• Selection of eight potential inhibitor molecules based on Glide score, binding mode, and hydrogen bond interactions.
• Free energy calculations using MMGBSA and druggability assessment via physicochemical property analysis.

Main Results:

• Identification of eight promising small molecules as potential NOG inhibitors.
• Prioritization of compounds based on binding energy and structural similarity.
• Evaluation of identified molecules for drug-likeness and potential therapeutic utility.

Conclusions:

• Novel potential NOG inhibitors have been identified through structure-based virtual screening.
• These compounds warrant further in vitro and in vivo validation for treating breast cancer bone metastasis.
• The identified molecules can serve as valuable tool compounds for studying BMP pathway functions.